Loading…
Structure‐based design, synthesis, and evaluation of Bcl‐2/Mcl‐1 dual inhibitors
Based on our previously reported Bcl‐2/Mcl‐1 dual inhibitor 4‐thiomorpholinyl‐2‐cyano‐3‐amidinophenalenone (A1) that simultaneously occupies the p2 and p4 hydrophobic pockets of Bcl‐2 and Mcl‐1, we optimized molecules with different bond angles of the groups extending to the p4 pocket and bulky hydr...
Saved in:
Published in: | Archiv der Pharmazie (Weinheim) 2020-05, Vol.353 (5), p.e2000005-n/a |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c3735-9cf5f3fc75d36b158dc5f967ce4e44df4bfab1eb7053c42788afdc08a85139713 |
---|---|
cites | cdi_FETCH-LOGICAL-c3735-9cf5f3fc75d36b158dc5f967ce4e44df4bfab1eb7053c42788afdc08a85139713 |
container_end_page | n/a |
container_issue | 5 |
container_start_page | e2000005 |
container_title | Archiv der Pharmazie (Weinheim) |
container_volume | 353 |
creator | Zhu, Junjie Wang, Ziqian Guo, Zongwei Zhang, Xiaodong Song, Ting Guo, Yafei Ji, Tong Zhang, Zhichao |
description | Based on our previously reported Bcl‐2/Mcl‐1 dual inhibitor 4‐thiomorpholinyl‐2‐cyano‐3‐amidinophenalenone (A1) that simultaneously occupies the p2 and p4 hydrophobic pockets of Bcl‐2 and Mcl‐1, we optimized molecules with different bond angles of the groups extending to the p4 pocket and bulky hydrophobic groups to explore p2. Research on structure–activity relationship resulted in a new derivative B4 that is capable of occupying both the p2 and p4 more deeply and completely than A1, with Ki values determined by fluorescence polarization assay (FPAs) improving to 0.31 μM for Bcl‐2 and 0.16 μM for Mcl‐1. Furthermore, B4 exhibited selective lethality on cancer cells over normal cells. It showed stronger apoptosis induction than (–)‐gossypol on a Bcl‐2/Mcl‐1‐dependent cancer cell line and killed an Mcl‐1‐dependent cell line which is resistant to ABT‐199 treatment.
Optimization of the previously reported Bcl‐2/Mcl‐1 dual inhibitor 4‐thiomorpholinyl‐2‐cyano‐3‐amidinophenalenone (A1) resulted in a new derivative B4 that is capable of occupying both the p2 and p4 hydrophobic pockets of Bcl‐2 and Mcl‐1 more deeply and completely than A1. B4 shows selective lethality on cancer cells over normal cells and stronger apoptosis induction than (–)‐gossypol on a Bcl‐2/Mcl‐1‐dependent cancer cell line. |
doi_str_mv | 10.1002/ardp.202000005 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2393984454</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2393984454</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3735-9cf5f3fc75d36b158dc5f967ce4e44df4bfab1eb7053c42788afdc08a85139713</originalsourceid><addsrcrecordid>eNqFkLlOAzEURS0EIiHQUiJLtJnE6ywlhFUKArG1lscLmWgyE-wxKB2fwDfyJUxICCWvea849z7pAHCI0QAjRIbS6fmAIIKWw7dAF3OCI4ZTtg26iMY8igmlHbDn_bQlKCJ8F3QowQmPCe-C54fGBdUEZ74-PnPpjYba-OKl6kO_qJpJe_s-lJWG5k2WQTZFXcHawlNVtgEyvPnZGOogS1hUkyIvmtr5fbBjZenNwXr3wNPF-ePoKhrfXl6PTsaRognlUaYst9SqhGsa55inWnGbxYkyzDCmLcutzLHJE8SpYiRJU2m1QqlMOaZZgmkPHK96565-DcY3YloHV7UvBaEZzVLGOGupwYpSrvbeGSvmrphJtxAYiaVGsdQoNhrbwNG6NuQzozf4r7cWyFbAe1GaxT914uT-7O6v_BtrtoEk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2393984454</pqid></control><display><type>article</type><title>Structure‐based design, synthesis, and evaluation of Bcl‐2/Mcl‐1 dual inhibitors</title><source>Wiley</source><creator>Zhu, Junjie ; Wang, Ziqian ; Guo, Zongwei ; Zhang, Xiaodong ; Song, Ting ; Guo, Yafei ; Ji, Tong ; Zhang, Zhichao</creator><creatorcontrib>Zhu, Junjie ; Wang, Ziqian ; Guo, Zongwei ; Zhang, Xiaodong ; Song, Ting ; Guo, Yafei ; Ji, Tong ; Zhang, Zhichao</creatorcontrib><description>Based on our previously reported Bcl‐2/Mcl‐1 dual inhibitor 4‐thiomorpholinyl‐2‐cyano‐3‐amidinophenalenone (A1) that simultaneously occupies the p2 and p4 hydrophobic pockets of Bcl‐2 and Mcl‐1, we optimized molecules with different bond angles of the groups extending to the p4 pocket and bulky hydrophobic groups to explore p2. Research on structure–activity relationship resulted in a new derivative B4 that is capable of occupying both the p2 and p4 more deeply and completely than A1, with Ki values determined by fluorescence polarization assay (FPAs) improving to 0.31 μM for Bcl‐2 and 0.16 μM for Mcl‐1. Furthermore, B4 exhibited selective lethality on cancer cells over normal cells. It showed stronger apoptosis induction than (–)‐gossypol on a Bcl‐2/Mcl‐1‐dependent cancer cell line and killed an Mcl‐1‐dependent cell line which is resistant to ABT‐199 treatment.
Optimization of the previously reported Bcl‐2/Mcl‐1 dual inhibitor 4‐thiomorpholinyl‐2‐cyano‐3‐amidinophenalenone (A1) resulted in a new derivative B4 that is capable of occupying both the p2 and p4 hydrophobic pockets of Bcl‐2 and Mcl‐1 more deeply and completely than A1. B4 shows selective lethality on cancer cells over normal cells and stronger apoptosis induction than (–)‐gossypol on a Bcl‐2/Mcl‐1‐dependent cancer cell line.</description><identifier>ISSN: 0365-6233</identifier><identifier>EISSN: 1521-4184</identifier><identifier>DOI: 10.1002/ardp.202000005</identifier><identifier>PMID: 32175625</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>anticancer activities ; Antineoplastic Agents - chemical synthesis ; Antineoplastic Agents - chemistry ; Antineoplastic Agents - pharmacology ; Apoptosis ; Apoptosis - drug effects ; Bcl‐2/Mcl‐1 dual inhibitor ; Cell Line, Tumor ; Cell Proliferation - drug effects ; Dose-Response Relationship, Drug ; Drug Design ; Drug Screening Assays, Antitumor ; HEK293 Cells ; Humans ; Molecular Docking Simulation ; Molecular Structure ; Myeloid Cell Leukemia Sequence 1 Protein - antagonists & inhibitors ; Phenalenes - chemical synthesis ; Phenalenes - chemistry ; Phenalenes - pharmacology ; Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors ; Structure-Activity Relationship</subject><ispartof>Archiv der Pharmazie (Weinheim), 2020-05, Vol.353 (5), p.e2000005-n/a</ispartof><rights>2020 Deutsche Pharmazeutische Gesellschaft</rights><rights>2020 Deutsche Pharmazeutische Gesellschaft.</rights><rights>2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3735-9cf5f3fc75d36b158dc5f967ce4e44df4bfab1eb7053c42788afdc08a85139713</citedby><cites>FETCH-LOGICAL-c3735-9cf5f3fc75d36b158dc5f967ce4e44df4bfab1eb7053c42788afdc08a85139713</cites><orcidid>0000-0002-2774-2384</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32175625$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhu, Junjie</creatorcontrib><creatorcontrib>Wang, Ziqian</creatorcontrib><creatorcontrib>Guo, Zongwei</creatorcontrib><creatorcontrib>Zhang, Xiaodong</creatorcontrib><creatorcontrib>Song, Ting</creatorcontrib><creatorcontrib>Guo, Yafei</creatorcontrib><creatorcontrib>Ji, Tong</creatorcontrib><creatorcontrib>Zhang, Zhichao</creatorcontrib><title>Structure‐based design, synthesis, and evaluation of Bcl‐2/Mcl‐1 dual inhibitors</title><title>Archiv der Pharmazie (Weinheim)</title><addtitle>Arch Pharm (Weinheim)</addtitle><description>Based on our previously reported Bcl‐2/Mcl‐1 dual inhibitor 4‐thiomorpholinyl‐2‐cyano‐3‐amidinophenalenone (A1) that simultaneously occupies the p2 and p4 hydrophobic pockets of Bcl‐2 and Mcl‐1, we optimized molecules with different bond angles of the groups extending to the p4 pocket and bulky hydrophobic groups to explore p2. Research on structure–activity relationship resulted in a new derivative B4 that is capable of occupying both the p2 and p4 more deeply and completely than A1, with Ki values determined by fluorescence polarization assay (FPAs) improving to 0.31 μM for Bcl‐2 and 0.16 μM for Mcl‐1. Furthermore, B4 exhibited selective lethality on cancer cells over normal cells. It showed stronger apoptosis induction than (–)‐gossypol on a Bcl‐2/Mcl‐1‐dependent cancer cell line and killed an Mcl‐1‐dependent cell line which is resistant to ABT‐199 treatment.
Optimization of the previously reported Bcl‐2/Mcl‐1 dual inhibitor 4‐thiomorpholinyl‐2‐cyano‐3‐amidinophenalenone (A1) resulted in a new derivative B4 that is capable of occupying both the p2 and p4 hydrophobic pockets of Bcl‐2 and Mcl‐1 more deeply and completely than A1. B4 shows selective lethality on cancer cells over normal cells and stronger apoptosis induction than (–)‐gossypol on a Bcl‐2/Mcl‐1‐dependent cancer cell line.</description><subject>anticancer activities</subject><subject>Antineoplastic Agents - chemical synthesis</subject><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Bcl‐2/Mcl‐1 dual inhibitor</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation - drug effects</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Design</subject><subject>Drug Screening Assays, Antitumor</subject><subject>HEK293 Cells</subject><subject>Humans</subject><subject>Molecular Docking Simulation</subject><subject>Molecular Structure</subject><subject>Myeloid Cell Leukemia Sequence 1 Protein - antagonists & inhibitors</subject><subject>Phenalenes - chemical synthesis</subject><subject>Phenalenes - chemistry</subject><subject>Phenalenes - pharmacology</subject><subject>Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors</subject><subject>Structure-Activity Relationship</subject><issn>0365-6233</issn><issn>1521-4184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqFkLlOAzEURS0EIiHQUiJLtJnE6ywlhFUKArG1lscLmWgyE-wxKB2fwDfyJUxICCWvea849z7pAHCI0QAjRIbS6fmAIIKWw7dAF3OCI4ZTtg26iMY8igmlHbDn_bQlKCJ8F3QowQmPCe-C54fGBdUEZ74-PnPpjYba-OKl6kO_qJpJe_s-lJWG5k2WQTZFXcHawlNVtgEyvPnZGOogS1hUkyIvmtr5fbBjZenNwXr3wNPF-ePoKhrfXl6PTsaRognlUaYst9SqhGsa55inWnGbxYkyzDCmLcutzLHJE8SpYiRJU2m1QqlMOaZZgmkPHK96565-DcY3YloHV7UvBaEZzVLGOGupwYpSrvbeGSvmrphJtxAYiaVGsdQoNhrbwNG6NuQzozf4r7cWyFbAe1GaxT914uT-7O6v_BtrtoEk</recordid><startdate>202005</startdate><enddate>202005</enddate><creator>Zhu, Junjie</creator><creator>Wang, Ziqian</creator><creator>Guo, Zongwei</creator><creator>Zhang, Xiaodong</creator><creator>Song, Ting</creator><creator>Guo, Yafei</creator><creator>Ji, Tong</creator><creator>Zhang, Zhichao</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><orcidid>https://orcid.org/0000-0002-2774-2384</orcidid></search><sort><creationdate>202005</creationdate><title>Structure‐based design, synthesis, and evaluation of Bcl‐2/Mcl‐1 dual inhibitors</title><author>Zhu, Junjie ; Wang, Ziqian ; Guo, Zongwei ; Zhang, Xiaodong ; Song, Ting ; Guo, Yafei ; Ji, Tong ; Zhang, Zhichao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3735-9cf5f3fc75d36b158dc5f967ce4e44df4bfab1eb7053c42788afdc08a85139713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>anticancer activities</topic><topic>Antineoplastic Agents - chemical synthesis</topic><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Bcl‐2/Mcl‐1 dual inhibitor</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation - drug effects</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Design</topic><topic>Drug Screening Assays, Antitumor</topic><topic>HEK293 Cells</topic><topic>Humans</topic><topic>Molecular Docking Simulation</topic><topic>Molecular Structure</topic><topic>Myeloid Cell Leukemia Sequence 1 Protein - antagonists & inhibitors</topic><topic>Phenalenes - chemical synthesis</topic><topic>Phenalenes - chemistry</topic><topic>Phenalenes - pharmacology</topic><topic>Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors</topic><topic>Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhu, Junjie</creatorcontrib><creatorcontrib>Wang, Ziqian</creatorcontrib><creatorcontrib>Guo, Zongwei</creatorcontrib><creatorcontrib>Zhang, Xiaodong</creatorcontrib><creatorcontrib>Song, Ting</creatorcontrib><creatorcontrib>Guo, Yafei</creatorcontrib><creatorcontrib>Ji, Tong</creatorcontrib><creatorcontrib>Zhang, Zhichao</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Archiv der Pharmazie (Weinheim)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhu, Junjie</au><au>Wang, Ziqian</au><au>Guo, Zongwei</au><au>Zhang, Xiaodong</au><au>Song, Ting</au><au>Guo, Yafei</au><au>Ji, Tong</au><au>Zhang, Zhichao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Structure‐based design, synthesis, and evaluation of Bcl‐2/Mcl‐1 dual inhibitors</atitle><jtitle>Archiv der Pharmazie (Weinheim)</jtitle><addtitle>Arch Pharm (Weinheim)</addtitle><date>2020-05</date><risdate>2020</risdate><volume>353</volume><issue>5</issue><spage>e2000005</spage><epage>n/a</epage><pages>e2000005-n/a</pages><issn>0365-6233</issn><eissn>1521-4184</eissn><abstract>Based on our previously reported Bcl‐2/Mcl‐1 dual inhibitor 4‐thiomorpholinyl‐2‐cyano‐3‐amidinophenalenone (A1) that simultaneously occupies the p2 and p4 hydrophobic pockets of Bcl‐2 and Mcl‐1, we optimized molecules with different bond angles of the groups extending to the p4 pocket and bulky hydrophobic groups to explore p2. Research on structure–activity relationship resulted in a new derivative B4 that is capable of occupying both the p2 and p4 more deeply and completely than A1, with Ki values determined by fluorescence polarization assay (FPAs) improving to 0.31 μM for Bcl‐2 and 0.16 μM for Mcl‐1. Furthermore, B4 exhibited selective lethality on cancer cells over normal cells. It showed stronger apoptosis induction than (–)‐gossypol on a Bcl‐2/Mcl‐1‐dependent cancer cell line and killed an Mcl‐1‐dependent cell line which is resistant to ABT‐199 treatment.
Optimization of the previously reported Bcl‐2/Mcl‐1 dual inhibitor 4‐thiomorpholinyl‐2‐cyano‐3‐amidinophenalenone (A1) resulted in a new derivative B4 that is capable of occupying both the p2 and p4 hydrophobic pockets of Bcl‐2 and Mcl‐1 more deeply and completely than A1. B4 shows selective lethality on cancer cells over normal cells and stronger apoptosis induction than (–)‐gossypol on a Bcl‐2/Mcl‐1‐dependent cancer cell line.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32175625</pmid><doi>10.1002/ardp.202000005</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-2774-2384</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0365-6233 |
ispartof | Archiv der Pharmazie (Weinheim), 2020-05, Vol.353 (5), p.e2000005-n/a |
issn | 0365-6233 1521-4184 |
language | eng |
recordid | cdi_proquest_journals_2393984454 |
source | Wiley |
subjects | anticancer activities Antineoplastic Agents - chemical synthesis Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology Apoptosis Apoptosis - drug effects Bcl‐2/Mcl‐1 dual inhibitor Cell Line, Tumor Cell Proliferation - drug effects Dose-Response Relationship, Drug Drug Design Drug Screening Assays, Antitumor HEK293 Cells Humans Molecular Docking Simulation Molecular Structure Myeloid Cell Leukemia Sequence 1 Protein - antagonists & inhibitors Phenalenes - chemical synthesis Phenalenes - chemistry Phenalenes - pharmacology Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors Structure-Activity Relationship |
title | Structure‐based design, synthesis, and evaluation of Bcl‐2/Mcl‐1 dual inhibitors |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T19%3A41%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Structure%E2%80%90based%20design,%20synthesis,%20and%20evaluation%20of%20Bcl%E2%80%902/Mcl%E2%80%901%20dual%20inhibitors&rft.jtitle=Archiv%20der%20Pharmazie%20(Weinheim)&rft.au=Zhu,%20Junjie&rft.date=2020-05&rft.volume=353&rft.issue=5&rft.spage=e2000005&rft.epage=n/a&rft.pages=e2000005-n/a&rft.issn=0365-6233&rft.eissn=1521-4184&rft_id=info:doi/10.1002/ardp.202000005&rft_dat=%3Cproquest_cross%3E2393984454%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3735-9cf5f3fc75d36b158dc5f967ce4e44df4bfab1eb7053c42788afdc08a85139713%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2393984454&rft_id=info:pmid/32175625&rfr_iscdi=true |